Abstract 203P
Background
The interaction between the immune system and the tumor microenvironment significantly impacts cancer progression and treatment response. Macrophages, with their diverse functional states, play a crucial role in this interplay. Identifying accurate markers for macrophage infiltration is vital for understanding their roles and therapeutic potential.
Methods
Immunai addresses this challenge by developing single cell atlases. Employing state-of-the-art single cell RNA sequencing (scRNA-seq) technologies, Immunai generates comprehensive and high-resolution transcriptomics data from diverse tumor samples, encompassing a wide range of cancer types. The establishment of scRNA-seq data atlases and references enables the identification of distinct macrophage populations within the tumor microenvironment, as well as their heterogeneity and functional states. Utilizing advanced computational algorithms and analytical pipelines, Immunai systematically analyses scRNA-seq datasets to uncover specific molecular signatures associated with macrophage infiltration.
Results
In the presented work, Immunai's approach enabled the discovery of novel macrophage-specific markers that can serve as valuable tools for both basic research and clinical applications. The identified markers offer insights into the dynamic nature of macrophage populations within the tumor microenvironment and provide potential avenues for the development of immunotherapies targeting tumor-associated macrophages. Moreover, these markers hold promise as diagnostic and prognostic indicators, aiding in patient stratification and personalized treatment strategies.
Conclusions
Immunai's approach provides a significant contribution to immuno-oncology and novel therapeutic approaches.
Legal entity responsible for the study
Immunai.
Funding
Immunai.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
146P - A Novel Allosteric Oral Immunotherapy Small Molecule Modulates Adenosine 2A Receptor Signaling and Restores Anti-Tumor Immune Responses
Presenter: David Pejoski
Session: Poster Display
147P - Pre-clinical evaluation and safety profile of the highly selective anti-VISTA antibody K01401-020
Presenter: Geneviève Gueguen Dorbes
Session: Poster Display
148P - HexaBody-OX40, a novel Fc_ receptor crosslinking-independent OX40-targeting antibody, exhibits agonistic activity in vitro and antitumor activity in vivo
Presenter: Kristel Kemper
Session: Poster Display
149P - HLA/SIRPa bispecifics-A novel multitarget therapeutic strategy to induce potent anti-tumor immune responses
Presenter: anahita rafiei
Session: Poster Display
150P - Chemotherapy in combination with Toll-like receptor agonism promoted antitumor immune response in triple negative breast cancer
Presenter: Eunice Dotse
Session: Poster Display
151P - Tumor organoid-derived TIL therapy for colorectal cancer
Presenter: Marc Leushacke
Session: Poster Display
152P - Discovery of best-in-class dual-acting A2AR/A2BR antagonists that are functional in high adenosine environment
Presenter: Nainesh Katagihallimath
Session: Poster Display
153P - Discovery of a Novel, Dual CD73 and PD-1 Targeting Multispecific Drug Fc-Conjugate (DFC) for the Treatment of Cancer
Presenter: James Levin
Session: Poster Display
154P - Computer-aided drug design based on CLDN4 ligand and its biological evaluation in ovarian cancer
Presenter: Yi Xu
Session: Poster Display
155P - A Phase 1 Study Exploring the Safety and Tolerability of the Small-Molecule PD-L1 Inhibitor INCB099280 in Select Advanced Solid Tumors
Presenter: Hans Prenen
Session: Poster Display